|
[1]
|
World Health Organization (2023) Global Tuberculosis Report 2023. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/global-tuberculosis-report-2023/global-tb-report-2023-factsheet.pdf?sfvrsn=f0dfc8a4_3&download=true
|
|
[2]
|
韩萍. 耐药结核病的流行现状及其治疗[J]. 上海医药, 2022, 43(15): 3-5+9.
|
|
[3]
|
Zhang, J., Gou, H., Hu, X., Hu, X., Shang, M., Zhou, J., et al. (2016) Status of Drug-Resistant Tuberculosis in China: A Systematic Review and Meta-Analysis. American Journal of Infection Control, 44, 671-676. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
赵飞, 杜昕, 李涛, 等. 基于世界卫生组织公共数据库的中国结核病流行趋势与预测[J]. 临床药物治疗杂志, 2018, 16(4): 1-3+8.
|
|
[5]
|
Pedersen, O.S., Holmgaard, F.B., Mikkelsen, M.K.D., Lange, C., Sotgiu, G., Lillebaek, T., et al. (2023) Global Treatment Outcomes of Extensively Drug-Resistant Tuberculosis in Adults: A Systematic Review and Meta-Analysis. Journal of Infection, 87, 177-189. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
杜姗姗, 沙巍. 肺结核短疗程治疗的研究进展[J]. 同济大学学报(医学版), 2024, 45(2): 303-309.
|
|
[7]
|
World Health Organization (2022) Global Tuberculosis Report 2022.
|
|
[8]
|
World Health Organization (2021) Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis.
|
|
[9]
|
首都医科大学附属北京胸科医院, 北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版) [J]. 中国防痨杂志, 2021, 43(9): 859-866.
|
|
[10]
|
Bagcchi, S. (2023) Who’s Global Tuberculosis Report 2022. The Lancet Microbe, 4, e20. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
周文强, 张爽, 初乃惠. 耐药肺结核全口服治疗方案研究的现状和展望[J]. 中国防痨杂志, 2021, 43(9): 879-882.
|
|
[12]
|
Conradie, F., Diacon, A.H., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., et al. (2020) Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine, 382, 893-902. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Conradie, F., Bagdasaryan, T.R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., et al. (2022) Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine, 387, 810-823. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Nyang’wa, B., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., et al. (2022) A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine, 387, 2331-2343. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
World Health Organization (2022) WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 Update. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
|
|
[16]
|
Solans, B.P., Imperial, M.Z., Olugbosi, M. and Savic, R.M. (2023) Analysis of Dynamic Efficacy Endpoints of the Nix-Tb Trial. Clinical Infectious Diseases, 76, 1903-1910. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lee, M., Lee, J., Carroll, M.W., Choi, H., Min, S., Song, T., et al. (2012) Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 367, 1508-1518. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
陈津红. 利奈唑胺用于耐多药肺结核治疗的现状[J]. 天津药学, 2022, 34(5): 67-73.
|
|
[19]
|
Agyeman, A.A. and Ofori-Asenso, R. (2016) Efficacy and Safety Profile of Linezolid in the Treatment of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Tuberculosis: A Systematic Review and Meta-Analysis. Annals of Clinical Microbiology and Antimicrobials, 15, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版) [J]. 中华结核和呼吸杂志, 2019, 42(10): 733-749.
|
|
[21]
|
World Health Organization (2018) Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis.
|
|
[22]
|
朱艳丽. 耐药结核病的诊疗新进展[J]. 中国社区医师, 2022, 38(15): 6-8.
|
|
[23]
|
周文强, 初乃惠. 耐药结核病治疗的进展[J]. 中国临床医生杂志, 2021, 39(7): 385-391.
|
|
[24]
|
高文英, 李涛. 经支气管镜介入治疗耐多药肺结核临床观察[J]. 中国医学工程, 2014, 22(9): 131-132.
|
|
[25]
|
张瑞娥. 经纤维支气管镜局部给药对耐多药肺结核病的治疗研究[J]. 中国防痨杂志, 2002, 4(1):16-18.
|
|
[26]
|
Mitnick, C.D., McGee, B. and Peloquin, C.A. (2009) Tuberculosis Pharmacotherapy: Strategies to Optimize Patient Care. Expert Opinion on Pharmacotherapy, 10, 381-401. [Google Scholar] [CrossRef] [PubMed]
|